AstraZeneca PLC (AZN)vsProtalix Biotherapeutics Inc (PLX)
AZN
AstraZeneca PLC
$157.97
-1.49%
HEALTHCARE · Cap: $263.09B
PLX
Protalix Biotherapeutics Inc
$2.37
+2.16%
HEALTHCARE · Cap: $190.15M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 80242% more annual revenue ($61.37B vs $76.38M). PLX leads profitability with a 20.1% profit margin vs 17.0%. PLX trades at a lower P/E of 12.4x. PLX earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PLX
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$157.97
$38.96 discount
Intrinsic value data unavailable for PLX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Strong operational efficiency at 62.6%
Revenue surging 233.7% year-over-year
Every $100 of equity generates 23 in profit
Keeps 20 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 1.0%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : PLX
The strongest argument for PLX centers on Operating Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 20.1% and operating margin at 62.6%. Revenue growth of 233.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while PLX is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
PLX is growing revenue faster at 233.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 60/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?